Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study
Xiaobin Zhang(Chengdu University), Yhi Wong(University of Hong Kong), Roelf Valkema(Active Medicine (United Kingdom)), Manon C.W. Spaander(Erasmus University Rotterdam), Tsung‐Min Hung(Chang Gung University), Bas P. L. Wijnhoven(Erasmus MC Cancer Institute), Yin‐Kai Chao(Chang Gung University), Zhentao Yu(Dalian Ocean University), Sjoerd M. Lagarde(University of Amsterdam), Simon Law(Inserm), Ben M. Eyck(Erasmus MC Cancer Institute), Qingsong Pang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jun Liu(Shanghai Jiao Tong University), Yang Yang(Beijing Institute of Education), Hongjing Jiang(Tianjin Medical University Cancer Institute and Hospital), Ka-On Lam(Chinese University of Hong Kong), Ming-Mo Hou(Chang Gung University), Ate van der Gaast(Erasmus MC), Berend J. van der Wilk(Erasmus MC Cancer Institute), J.J.B. van Lanschot(Erasmus MC)
Cited by 40
Related Papers
Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer
|Nature Genetics|2014|1.1k
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial
|Journal of Clinical Oncology|2018|976
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
|Nature Genetics|2009|788
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
|Journal of Clinical Oncology|2021|788